Teva Announces Sale of UK and Ireland Actavis Assets and Operations

JERUSALEM--(BUSINESS WIRE) -- Oct. 5, 2016 -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd) for an agreed value of GBP 603 million, subject to final approval from the European Commission.

The divestment of certain specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in the context of the review of the acquisition of Actavis Generics by Teva earlier this year. The sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva’s existing operations.

“The sale has been a success for Teva in that we have satisfied the EU Commission’s sale requirements for these businesses, subject to their final approval, and agreed on a good price for the assets. With the assets that it will retain, Teva will create an even stronger operation in the UK and Ireland,” commented Siggi Olafsson, President & CEO Global Generic Medicines Teva. “Teva is the leading provider of medicines to the UK National Health Service, and the addition of the retained Actavis assets strengthens our ability to be the partner of choice in these countries while preserving strong and healthy competition in a competitive marketplace.”

The transaction is expected to close in the next three months. Greenhill & Co. are serving as financial advisors to Teva, and Pinsent Masons are serving as legal counsel to Teva in respect of this transaction.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.

Source: http://www.tevapharm.com/